Compare MG & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MG | MYGN |
|---|---|---|
| Founded | 1978 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 481.7M | 481.6M |
| IPO Year | 2008 | 1996 |
| Metric | MG | MYGN |
|---|---|---|
| Price | $14.16 | $4.66 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $7.64 |
| AVG Volume (30 Days) | 151.8K | ★ 1.5M |
| Earning Date | 06-10-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.53 | N/A |
| Revenue | $700,970,000.00 | ★ $771,400,000.00 |
| Revenue This Year | $5.23 | $7.19 |
| Revenue Next Year | $3.13 | $5.64 |
| P/E Ratio | $26.91 | ★ N/A |
| Revenue Growth | N/A | ★ 2.33 |
| 52 Week Low | $7.06 | $3.76 |
| 52 Week High | $15.84 | $10.32 |
| Indicator | MG | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 42.92 | 41.35 |
| Support Level | $13.80 | $3.93 |
| Resistance Level | $14.96 | $5.63 |
| Average True Range (ATR) | 0.76 | 0.42 |
| MACD | -0.16 | 0.04 |
| Stochastic Oscillator | 40.07 | 21.43 |
MISTRAS Group Inc provides asset protection solutions and systems. The company evaluates the structural integrity and reliability of critical energy, industrial, and public infrastructure. The company's three operating segments are North America, International and Products and Systems, of which key revenue is derived from the North America segment. Services segment provides asset protection solutions predominantly in North America, with the large amount of concentration in the United States, followed by Canada, consisting of non-destructive testing, and inspection. The asset protection solutions include field inspections, consulting, maintenance, data management, access, monitoring and laboratory quality assurance.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.